Patients Icon

XPOVIO + Vd within 4 different treatment journeys

If you see patients like these in your practice, consider whether introducing a different class could be their next step.

Primary endpoint: mPFS in the ITT population1

mPFS: 13.9 months with XPOVIO + Vd (n=195) vs 9.5 months with Vd alone (n=207); HR: 0.70 (95% CI: 0.53, 0.93), P=0.0075)

These patients are not actual patients. These patient characteristics do not represent all patient types for whom XPOVIO may be appropriate.

Early lines of therapy

Later lines of therapy

Charles is ready to tackle RRMM with a different treatment class

Charles, 76

I want a proven treatment from my local doctor.”

Photo of Charles, an actor portrayal of someone living with multiple myeloma

Patient background

  • Likes his current doctor and wants to stay with them
  • Prefers to avoid traveling far from home or seeing additional specialists
  • Wants a treatment with an established safety profile

Treatment considerations

  • Transplant ineligible
  • Progressing following treatment with an anti-CD38 mAb
  • Has not been treated with a PI

Treatment history

1L treatment

  • DRd (daratumumab + lenalidomide + dexamethasone): 38 cycles

XPOVIO can meet Charles where he is

Icon representing a different treatment class

Introduces a different treatment class1

Icon representing tablet

Oral, once-weekly tablets are readily accessible and can be taken at home1,2*

Icon representing Home

Hospitalization is not required for administration or monitoring1

*XPOVIO® (selinexor) is a prescription medicine approved in combination with subcutaneous bortezomib injection and oral dexamethasone.1

Efficacy observed in multiple subgroups3,4

Chart showing treatment history for Charles Chart showing treatment history for Charles

Limitations of subgroup analyses:

  • These subgroup analyses were exploratory in nature, not included in the study objectives, and do not control for type 1 error
  • These subgroup analyses were not powered or adjusted for multiplicity to assess PFS/ORR across these subgroups

These subgroup data are derived from an updated efficacy analysis from the XVd trial.

Early lines of therapy

Charles is ready to tackle RRMM with a different treatment class

Patient background

  • Likes his current doctor and wants to stay with them
  • Prefers to avoid traveling far from home or seeing additional specialists
  • Wants a treatment with an established safety profile
Photo of Charles, an actor portrayal of someone living with multiple myeloma

I want a proven treatment from my local doctor.”

Treatment considerations

  • Transplant ineligible
  • Progressing following treatment with an anti-CD38 mAb
  • Has not been treated with a PI

Treatment history

1L treatment

  • DRd (daratumumab + lenalidomide + dexamethasone): 38 cycles

XPOVIO can meet Charles where he is

Icon representing a different treatment class

Introduces a different treatment class1

Icon representing tablet

Oral, once-weekly tablets are readily accessible and can be taken at home1,2*

Icon representing Home

Hospitalization is not required for administration or monitoring1

XPOVIO® (selinexor) is a prescription medicine approved in combination with subcutaneous bortezomib injection and oral dexamethasone.1

Efficacy observed in multiple subgroups4

Chart showing treatment history for Charles Chart showing treatment history for Charles

Limitations of subgroup analyses:

  • These subgroup analyses were exploratory in nature, not included in the study objectives, and do not control for type 1 error
  • These subgroup analyses were not powered or adjusted for multiplicity to assess PFS/ORR across these subgroups

These subgroup data are derived from an updated efficacy analysis from the XVd trial.

Patricia is ready for a different treatment class that is accessible for her

Patient background

  • Widow, lives independently and has no family living nearby
  • Lacks ability to drive long distances or stay away from home
  • Wants a treatment with an established safety profile
Photo of Patricia, an actor portrayal of someone living with multiple myeloma

I want an established therapy that’s accessible for me.”

Treatment considerations

  • High-risk cytogenetics
  • Renal impairment: CLCR of 52 mL/min
  • Progressed following treatment with an anti-CD38 mAb

Treatment history

1L treatment

  • RVd (lenalidomide + bortezomib + dexamethasone): 12 cycles
  • Maintenance lenalidomide: 16 cycles

2L treatment

  • DPd (daratumumab + pomalidomide + dexamethasone): 12 cycles

XPOVIO can meet Patricia where she is

Icon representing a different treatment class

Introduces a different treatment class1

Icon representing tablet

Oral, once-weekly tablets are readily accessible and can be taken at home1,2*

Icon representing Home

Hospitalization is not required for administration or monitoring1

XPOVIO® (selinexor) is a prescription medicine approved in combination with subcutaneous bortezomib injection and oral dexamethasone.1

Efficacy observed in multiple subgroups4

Chart showing treatment history for Patricia Chart showing treatment history for Patricia

Limitations of subgroup analyses:

  • These subgroup analyses were exploratory in nature, not included in the study objectives, and do not control for type 1 error
  • These subgroup analyses were not powered or adjusted for multiplicity to assess PFS/ORR across these subgroups

Includes any of del(17p), t(14;16), t(4;14), 1q21.

Tanya is ready for a different treatment class while awaiting CAR-T

Patient background

  • Pursuing CAR-T therapy now that her disease is progressing
  • Willing to travel to a treatment center to receive CAR-T
Photo of Patricia, an actor portrayal of someone living with multiple myeloma

I am pursuing CAR-T, but it’s going to take some time.”

Treatment considerations

  • High-risk cytogenetics
  • Renal impairment: CLCR of 40 mL/min
  • Consistent rising M-spike over last 3 treatment cycles

Treatment history

1L treatment

  • DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone): 8 cycles
  • ASCT
  • Maintenance lenalidomide + daratumumab: 18 cycles

2L treatment

  • KPd (carfilzomib + pomalidomide + dexamethasone): 7 cycles

Currently being evaluated for CAR-T

XPOVIO can meet Tanya where she is

Icon representing a different treatment class

Introduces a different treatment class1

Icon representing tablet

Oral, once-weekly tablets are readily accessible and can be taken at home1,2*

Icon representing Home

The majority of patients receive treatment in <1 week of prescription2

XPOVIO® (selinexor) is a prescription medicine approved in combination with subcutaneous bortezomib injection and oral dexamethasone.1

Efficacy observed in multiple subgroups4

Chart showing treatment history for Tanya Chart showing treatment history for Tanya

Limitations of subgroup analyses:

  • These subgroup analyses were exploratory in nature, not included in the study objectives, and do not control for type 1 error
  • These subgroup analyses were not powered or adjusted for multiplicity to assess PFS/ORR across these subgroups

Includes any of del(17p), t(14;16), t(4;14), 1q21.

David is determined to keep fighting with a different treatment class

Patient background

  • A lifelong fighter who is determined to continue treatment
  • Remains optimistic and hopeful
Photo of David, an actor portrayal of someone living with multiple myeloma

I’m fighting to be a part of every family moment.”

Treatment considerations

  • High-risk cytogenetics
  • Renal impairment: CLCR of 36 mL/min
  • Slowly rising M-spike over 2 cycles

Treatment history

1L treatment

  • RVd (lenalidomide + bortezomib + dexamethasone): 8 cycles
  • ASCT
  • Maintenance lenalidomide: 36 cycles

2L treatment

  • DKd (daratumumab + carfilzomib + dexamethasone): 12 cycles

3L treatment

  • EPd (elotuzumab + pomalidomide + dexamethasone): 8 cycles

4L treatment

  • Ciltacabtagene autoleucel: DOR of 12 months

5L treatment

  • Talquetamab: 4 cycles

XPOVIO can meet David where he is

Icon representing a different treatment class

Introduces a different treatment class1

Icon representing tablet

Oral, once-weekly tablets are readily accessible and can be taken at home1,2*

Icon representing Home

The majority of patients receive treatment in <1 week of prescription2

XPOVIO® (selinexor) is a prescription medicine approved in combination with subcutaneous bortezomib injection and oral dexamethasone.1

Efficacy observed in multiple subgroups4

Chart showing treatment history for David Chart showing treatment history for David

Limitations of subgroup analyses:

  • These subgroup analyses were exploratory in nature, not included in the study objectives, and do not control for type 1 error
  • These subgroup analyses were not powered or adjusted for multiplicity to assess PFS/ORR across these subgroups

Includes any of del(17p), t(14;16), t(4;14), 1q21.

XVd is an NCCN Category 1 Regimen5

Oral, once-weekly selinexor (XPOVIO) in combination with bortezomib and dexamethasone (XVd) is recommended by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as an NCCN Category 1§ therapeutic option in relapsed/refractory MM after 1 to 3 prior therapies.

§Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate

Next steps

Tanya receiving support

Help your patients receive

Dedicated support

KaryForward® is a patient support program for eligible XPOVIO patients and provides dedicated help with insurance information, financial assistance, and guidance from Nurse Case Managers.

  • Assistance with benefits investigation
  • Financial assistance
  • XPOVIO Copay Program
  • QuickStart and Bridge Programs
  • Dose Exchange Program
  • Nurse Case Manager support

Enroll your patients or learn more:

CALL 1-877-KARY4WD (1-877-527-9493) Monday through Friday, 8 AM to 8 PM ET or VISIT KaryForward.com/hcp

Learn More

All programs and support are subject to eligibility requirements.

Tanya receiving support

Abbreviations: 1/2/3/4/5L, first-/second-/third-/fourth-/fifth-line; AR, adverse reaction; ASCT, autologous stem cell transplant; BsAb, bispecific antibody; CAR-T, chimeric antigen receptor T-cell therapy; CI, confidence interval; CLCR, creatinine clearance; HR, hazard ratio; ITT, intent-to-treat; M-spike, monoclonal spike; mAb, monoclonal antibody; mPFS, median progression-free survival; ORR, overall response rate; PFS, progression-free survival; PI, proteasome inhibitor; Vd, bortezomib and dexamethasone; XVd, selinexor, bortezomib, and dexamethasone.

NCCN, National Comprehensive Cancer Network®.

References: 1. XPOVIO (selinexor) [prescribing information]. Newton, MA: Karyopharm Therapeutics, Inc. 2. Data on file. Karyopharm Therapeutics, Inc. 2021 [1]. 3. Data on file. Karyopharm Therapeutics, Inc. 2021 [2]. 4. Data on file. Karyopharm Therapeutics, Inc. 2021 [3]. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed June 3, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org.

+

INDICATION

XPOVIO® (selinexor) is a prescription medicine approved in combination with bortezomib and dexamethasone (XVd) to treat adult patients with multiple myeloma who have received at least one prior therapy.


IMPORTANT SAFETY INFORMATION

Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma.

Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Monitor patients for signs and symptoms of bleeding. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Neutropenia: XPOVIO can cause life-threatening neutropenia, potentially increasing the risk of infection.

Monitor more frequently during the first 3 months of treatment. Consider supportive measures, including antimicrobials and growth factors (e.g., G-CSF). Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.

Gastrointestinal Toxicity: XPOVIO can cause severe gastrointestinal toxicities in patients.

Nausea/Vomiting/Diarrhea: Provide prophylactic antiemetics or treatment as needed.

Anorexia/Weight Loss: Monitor weight, nutritional status, and volume status at baseline and throughout treatment and provide nutritional support, fluids, and electrolyte repletion as clinically indicated.

Hyponatremia: XPOVIO can cause severe or life-threatening hyponatremia.

Monitor sodium level at baseline and throughout treatment.

Serious Infection: XPOVIO can cause serious and fatal infections. Atypical infections reported after taking XPOVIO include, but are not limited to, fungal pneumonia and herpesvirus infection.

Neurological Toxicity: XPOVIO can cause life-threatening neurological toxicities.

Coadministration of XPOVIO with other products that cause dizziness or mental status changes may increase the risk of neurological toxicity.

Advise patients to refrain from driving and engaging in hazardous occupations or activities, until the neurological toxicity fully resolves. Institute fall precautions as appropriate.

Embryo-Fetal Toxicity: XPOVIO can cause fetal harm when administered to a pregnant woman.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with a female partner of reproductive potential to use effective contraception during treatment with XPOVIO and for 1 week after the last dose.

Cataracts: New onset or exacerbation of cataract has occurred during treatment with XPOVIO. The incidence of new onset or worsening cataract requiring clinical intervention was reported.

ADVERSE REACTIONS

The most common adverse reactions (ARs) (≥20%) in patients with multiple myeloma who received XVd were fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract, and vomiting.

Grade 3-4 laboratory abnormalities (≥10%) were thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia.

Fatal ARs occurred in 6% of patients within 30 days of last treatment. Serious ARs occurred in 52% of patients. Treatment discontinuation rate due to ARs was 19%. The most frequent ARs requiring permanent discontinuation in >2% of patients included fatigue, nausea, thrombocytopenia, decreased appetite, peripheral neuropathy and vomiting. Adverse reactions led to XPOVIO dose interruption in 83% of patients and dose reduction in 64% of patients.

USE IN SPECIFIC POPULATIONS

No overall difference in effectiveness of XPOVIO was observed in patients >65 years old when compared with younger patients. Patients ≥65 years old had a higher incidence of discontinuation due to an adverse reaction (AR) and a higher incidence of serious ARs than younger patients.

The effect of end-stage renal disease (CLCR <15 mL/min) or hemodialysis on XPOVIO pharmacokinetics is unknown.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1-888-209-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

© 2025 Karyopharm Therapeutics Inc.

X